Abbott Laboratories (SWX:ABT)
102.00
-2.00 (-1.92%)
Jul 31, 2025, 11:52 PM CET
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $11.37B USD in the quarter ending September 30, 2025, with 6.90% growth. This brings the company's revenue in the last twelve months to $43.84B, up 6.37% year-over-year. In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth.
Revenue (ttm)
$43.84B
Revenue Growth
+6.37%
P/S Ratio
5.05
Revenue / Employee
$384.59K
Employees
114,000
Market Cap
176.40B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Sandoz Group AG | 8.42B |
Alcon | 7.97B |
Lonza Group AG | 7.09B |
Galenica AG | 4.03B |
Sonova Holding AG | 3.87B |
Galderma Group AG | 3.73B |
Abbott Laboratories News
- 19 hours ago - Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports - Reuters
- 3 days ago - Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming - Seeking Alpha
- 4 days ago - Peter Lynch Detailed Fundamental Analysis - ABT - Nasdaq
- 4 days ago - S&P 500 Analyst Moves: ABT - Nasdaq
- 5 days ago - Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength - Benzinga
- 5 days ago - These Analysts Revise Their Forecasts On Abbott Following Q3 Results - Benzinga
- 5 days ago - These Analysts Revise Their Forecasts On Abbott Following Q3 Results - Benzinga
- 5 days ago - Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $146 | ABT Stock News - GuruFocus